We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+38.74%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.72B
AUM Growth
+$518M
Cap. Flow
+$119M
Cap. Flow %
6.94%
Top 10 Hldgs %
67.52%
Holding
71
New
13
Increased
19
Reduced
9
Closed
13

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$43.8M
2
GILD icon
Gilead Sciences
GILD
+$30.4M
3
AZN icon
AstraZeneca
AZN
+$24.5M
4
ISRG icon
Intuitive Surgical
ISRG
+$20.7M
5
MRK icon
Merck
MRK
+$19.9M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$30.5M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21.1M
3
RGNX icon
Regenxbio
RGNX
+$16.7M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$15.8M
5
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 91.36%
2 Miscellaneous 8.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GERN icon
51
CALL
Geron
GERN
$899M
$2.51M 0.15%
1,072,100
+72,100
+7% +$161K
IMGN
52
DELISTED
Immunogen Inc
IMGN
$2.4M 0.14%
502,393
-638,395
-56% -$3.37M
NGM
53
CALL
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$1.96M 0.11%
+150,000
New +$2.27M
OBSV
54
DELISTED
ObsEva SA Ordinary Shares
OBSV
$675K 0.04%
4,749,623
– –
SYBX
55
DELISTED
Synlogic
SYBX
$546K 0.03%
38,331
– –
PDSB icon
56
PDS Biotechnology
PDSB
$16.4M
$424K 0.02%
142,635
– –
FUSN
57
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$352K 0.02%
117,099
+39,033
+50% +$97.5K
AMLX icon
58
Amylyx Pharmaceuticals
AMLX
$3.61B
– –
-187,381
Closed -$3.61M
ARGX icon
59
argenx
ARGX
$62.7B
– –
-15,000
Closed -$5.68M
CLDX icon
60
Celldex Therapeutics
CLDX
$3.05B
– –
-48,304
Closed -$1.3M
NVO
61
Novo Nordisk
NVO
$197B
– –
-547,746
Closed -$30.5M
PTGX icon
62
CALL
Protagonist Therapeutics
PTGX
$9.39B
– –
-100,000
Closed -$791K
VRTX icon
63
Vertex Pharmaceuticals
VRTX
$132B
– –
-74,758
Closed -$21.1M
XBI icon
64
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.1B
– –
-400,000
Closed -$29.7M
XNCR icon
65
Xencor
XNCR
$1.85B
– –
-158,164
Closed -$4.33M
SGEN
66
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-27,894
Closed -$4.94M
JNCE
67
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-981,928
Closed -$2.98M
CCXI
68
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-250,000
Closed -$6.2M
CCXI
69
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-636,659
Closed -$15.8M
HZNP
70
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-100,297
Closed -$8M
1 2
3

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q3 2022 Portfolio in Review

As of Q3 2022, Sofinnova Investments held 71 positions worth $1.72B, up 43% from $1.2B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Sofinnova Investments deployed $119M of net new capital in Q3 2022, opening 13 new positions and adding to 19 existing holdings. Its largest new stake was Gilead Sciences: 482,400 shares worth $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 93% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Regenxbio, an estimated $16.7M trimmed.

  • Sofinnova Investments's largest Q3 2022 buy was Gilead Sciences: 482,400 shares worth $29.8M.
  • Sofinnova Investments added most to Sanofi in Q3 2022, an estimated $43.8M increase.
  • Sofinnova Investments's biggest Q3 2022 reduction was Regenxbio, cutting an estimated $16.7M.
  • Sofinnova Investments fully exited Novo Nordisk in Q3 2022, selling an estimated $30.5M.
  • Sofinnova Investments's ten largest holdings make up 68% of its $1.72B portfolio in Q3 2022.
  • Sofinnova Investments opened 13 new positions and closed 13 in Q3 2022.
  • Sofinnova Investments's portfolio value rose 43% quarter-over-quarter to $1.72B.

Based on Sofinnova Investments's 13F filing for Q3 2022, filed 8 Nov 2022.